Lycia Therapeutics priced an initial public offering at a valuation backed by $318 million raised, positioning the company as a protein-degradation specialist. Proceeds from the IPO support development of multiple therapies, including programs targeting allergic conditions and Graves’ disease. The IPO funding is designed to carry a protein-degrader pipeline through further preclinical-to-clinical transitions. For the field, it reflects sustained capital interest in degradation platforms, especially where novel target engagement may translate into improved therapeutic indexes. With Graves’ disease remaining an immuno-endocrine challenge and allergic indications requiring careful safety profiling, Lycia’s early-stage programs will be closely watched for target validation, biomarker engagement, and tolerability signals as development advances.